Since its origin, the mission of ECR Pharmaceuticals has been to develop dosage forms and dosing formats that enhance patient convenience and compliance which in turn improves patient outcomes. ECR is committed to the manufacture of products of unexcelled quality and to assure that these are available to patients at an affordable price. This philosophy has been reduced to a simple statement: "Quality Products at a Price the Patient Can Afford". ECR places this phrase on virtually all literature, correspondence, and other information it produces as a daily reminder to our employees and customers of the company's continuing commitment to healthcare professionals and patients.

ECR Pharmaceuticals was formed in 1990 by three former AH Robins executives, E. Claiborne Robins, Jr., Davis S. Caskey, and Dr. Robert S. Murphey, to continue their long standing interests in the pharmaceutical industry. As the firm evolved, its focus became the development of improved dosage forms of widely used specialty and primary care products. These formulations help improve patient convenience and much needed therapeutic compliance. More recently ECR has expanded its product portfolio to include dermatological and wound care products.

In 2007 the firm received its first NDA for the once daily dosed musculoskeletal relaxant, Amrix® (cyclobenzaprine HCl, extended release). In 2008 ECR was granted its first ANDA for dexamethasone tablets. The company continues to pursue internally developed and external licensing opportunities.

In February, 2009 ECR was acquired by Hi-Tech Pharmacal, Amityville, NY, a major supplier of liquid, generic prescription products as well as branded OTC pharmaceuticals. (See Newsline). The combined capabilities and synergy of the two companies markedly enhanced the development, licensing, and marketing of various product opportunities. Product life cycles have improved and Hi-Tech's position in both the branded and generic marketplace has been solidified. ECR operates as a wholly owned subsidiary of Hi-Tech.

ECR products are distributed nationwide and are promoted to healthcare professionals and pharmacies through the firm's expanding sales force. The company has appropriately positioned itself and its sales organization to market not only those products developed internally but to be responsive to product opportunities which may come available through various other sources. It continues to aggressively pursue product technologies which improve patient convenience and compliance, and which provides enhanced patient therapy and outcomes. It does so with the mission and vision to provide quality, affordable pharmaceutical products to patients and physicians.